Trelegy Dosing
Trelegy (fluticasone furoate/umeclidinium/vilanterol) is administered as one inhalation of 100/62.5/25 mcg once daily via the Ellipta inhaler. 1, 2
Standard Dosing Regimen
- Single fixed dose: One inhalation once daily in the morning of FF/UMEC/VI 100/62.5/25 mcg 3, 4
- Device: Delivered via the Ellipta dry powder inhaler 1, 5
- Timing: Once-daily administration, typically in the morning 3, 4
Clinical Indications for Use
- Target population: Adults with moderate to severe COPD who are not adequately controlled on dual therapy (ICS/LABA combination) 2, 6
- Specific criteria: Patients with persistent moderate to severe dyspnea despite dual therapy, or those at high risk of COPD exacerbations 1
- Disease severity: Typically reserved for patients with FEV1 < 50% predicted, or FEV1 < 80% predicted with ≥2 moderate or 1 severe exacerbation in the prior year 4
Key Dosing Considerations
No dose adjustments are available - Trelegy comes only in the single fixed-dose combination of 100/62.5/25 mcg, unlike some other inhaled medications that offer multiple strength options 2, 3
Frequency advantage: The once-daily dosing of Trelegy contrasts with many multiple-inhaler triple therapy regimens that require twice-daily administration, potentially improving adherence 1, 4
Administration Technique
- Administer at the same time each day for consistency 5
- The Ellipta device is a breath-activated dry powder inhaler requiring proper inhalation technique 3
- Patient education on proper inhaler technique is essential when initiating therapy 1
Common Pitfalls to Avoid
- Do not increase the dose: There is no evidence supporting higher doses, and the medication is only available in one strength 2
- Do not use as rescue medication: Trelegy is maintenance therapy only; patients need a separate short-acting bronchodilator for acute symptom relief 6
- Avoid abrupt discontinuation: If tapering is needed, it should be gradual to prevent severe exacerbations 7